Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia

Journal of Neuroscience Research

Volumn 77, Issue 3, 2004, Pages 378-390

  Fisher, Beth E ^b   Petzinger, Giselle M ^a   Nixon, Kerry ^a   Hogg, Elizabeth ^a   Bremmer, Samuel ^c   Meshul, Charles K ^c,d   Jakowec, Michael W ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Dopamine receptors; Dopamine transporter; Glutamate; MPTP; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOWN REGULATION; ENDURANCE; EXTRAPYRAMIDAL SYNDROME; GENETIC TRANSCRIPTION; IMMUNOELECTRON MICROSCOPY; MALE; MOUSE; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RUNNING; TREADMILL EXERCISE; VELOCITY;

ANIMALS; BASAL GANGLIA; BEHAVIOR, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MPTP POISONING; NERVE TISSUE PROTEINS; NEURONAL PLASTICITY; PHYSICAL CONDITIONING, ANIMAL; TYROSINE 3-MONOOXYGENASE;

EID: 3242795769     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20162     Document Type: Article

References (40)

1. Bland ST, Gonzale RA, Schauert T. 1999. Movement-related glutamate levels in rat hippocampus, striatum, and sensorimotor cortex. Neurosci Lett 277:119-122.
2. Burke RE, Cadet JL, Kent JD, Karanas AL, Jackson-Lewis V. 1990. An assessment of the validity of densitometric measures of striatal tyrosine hydroxylase-positive fibers: relationship to apomorphine-induced rotations in 6-hydroxydopamine lesioned rats. J Neurosci Methods 35:63-73.
3. Cepeda C, Levine MS. 1998. Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev Neurosci 20:1-18.
4. Cepeda C, Buchwald NA, Levine MS. 1993. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci USA 90:9576-9580.
5. Cohen AD, Tillerson JL, Smith AD, Schallert T, Zigmond MJ. 2003. Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. J Neurochem 85:299-305.
6. Cotman CW, Berchtold NC. 2002. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci 25:295-301.
7. Fisher B, Sullivan KJ. 2001. Activity-dependent factors affecting post-stroke functional outcomes. Topics Stroke Rehabil 8:31-44.
8. Fukai T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G, Harrison DG. 2000. Regulation of the vascular extracellular Superoxide dismutase by nitric oxide and exercise training. J Clin Invest 105:1631-1639.
9. Gainetdinov RR, Sotnikova TD, Caron MG. 2002. Monoamine transporter pharmacology and mutant mice. Trends Pharmacol Sci 23:367-373.
10. Gerfen CR. 2000. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 23(Suppl):64-70.
11. Gerfen CR, Keefe KA, Gauda EB. 1995. D1 and D2 dopamine receptor function in the striatum: coactivation of D1- and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene responses in D1-containing neurons. J Neurosci 15:8167-8176.
12. Gomez-Pinilla F, Ying Z, Roy RR, Molteni R, Edgerton VR. 2002. Voluntary exercise induces a BDNF-mediated mechanism that promotes neuroplasticity. Neurophysiol 88:2187-2195.
13. Hepler JR, Toomim CS, McCarthy KD, Conti F, Battaglia G, Rustioni A, Petrusz P. 1988. Characterization of antisera to glutamate and aspartate. J Histochem Cytochem 36:13-22.
14. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. 1995. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4:257-269.
15. Jakowec MW, Nixon K, Hogg L, McNeill T, Petzinger GM. 2004. Tyrosine hydroxylase and dopamine transporter expression following 4-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine-induced neurodegeneration in the mouse nigrostriatal pathway. J Neurosci Res 76:539-550.
16. Jakowec MW, Fisher B, Nixon K, Hogg L, Meshul C, Bremmer S, McNeill T, Petzinger GM. 2003. Neuroplasticity in the MPTP-lesioned mouse and non-human primate. Ann N Y Acad Sci 991:298-301.
17. Kempermann G, van Praag H, Gage FH. 2000. Activity-dependent regulation of neuronal plasticity and self repair. Prog Brain Res 127:35-48.
18. Kojda G, Cheng YC, Burchfield J, Harrison DG. 2001. Dysfunctional regulation of endothelial nitric oxide synthase (eNOS) expression in response to exercise in mice lacking one eNOS gene. Circulation 103:2939-2844.
19. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature 227:680-685.
20. LaHoste GJ, Marshall JF. 1993. The role of dopamine in the maintenance and breakdown of D1/D2 synergism. Brain Res 611:108-116.
21. Liste I, Rodriguez-Pallares J, Caruncho HJ, Labandeira-Garcia JL. 1999. Locomotor-activity-induced changes in striatal levels of preprotachykinin and preproenkephalin mRNA. Regulation by the dopaminergic and glutamatergic systems. Brain Res Mol Brain Res 70:74-83.
22. Meeusen R, Smolders I, Sarre S, de Meirleir K, Keizer H, Serneels M, Ebinger G, Michotte Y. 1997. Endurance training effects on neurotransmitter release in rat striatum: an in vivo microdialysis study. Acta Physiol Scand 159:335-341.
23. Meshul CK, Noguchi K, Emre N, Ellison G. 1998. Cocaine-induced changes in glutamate and GABA immunolabeling within rat habenula and nucleus accumbens. Synapse 30:211-220.
24. Meshul CK, Cogen JP, Cheng HW, Moore C, Krentz L, McNeill TH. 2000. Alterations in rat striatal glutamate synapses following a lesion of the cortico- and/or nigrostriatal pathway. Exp Neurol 165:191-206.
25. Mortensen OV, Amara SG. 2003. Dynamic regulation of the dopamine transporter. Eur J Pharmacol 479:159-170.
26. Page G, Peeters M, Najimi M, Maloteaux JM, Hermans E. 2001. Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluRS in rat striatal synaptosomes through phosphorylation mediated processes. J Neurochem 76:1282-1290.
27. Perrone-Calano C, Tino A, Amadoro G, Pernas-Alonso R, di Porzio U. 1996. Dopamine transporter gene expression in rat mesencephalic dopaminergic neurons is increased by direct interaction with target striatal cells in vitro. Brain Res Mol Brain Res 39:160-166.
28. Phend KD, Weinberg RJ, Rustioni A. 1992. Techniques to optimize post-embedding single and double staining for amino acid neurotransmitters. J Histochem Cytochem 40:1011-1020.
29. Ricaurte GA, Langston JW, DeLanney LE, Irwin I, Peroutka SJ, Forno LS. 1986. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res 376:117-124.
30. Sasco AJ, Paffenbarger RS Jr, Gendre I, Wing AL. 1992. The role of physical exercise in the occurrence of Parkinson's disease. Arch Neurol 49:360-365.
31. Sauer H, Oertel W. 1994. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neurosci 59:401-415.
32. Sedelis M, Schwarting RK, Huston JP. 2001. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 125:109-125.
33. Starr MS. 1995. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 19:264-293.
34. Starr MS, Starr BS. 1994. Comparison of the effects of NMDA and AMPA antagonists on the locomotor activity induced by selective D1 and D2 dopamine agonists in reserpine-treated mice. Psychopharmacology (Bed) 114:469-476.
35. Starr MS, Starr BS, Kaur S. 1997. Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease. Neurosci Biobehav Rev 21:437-446.
36. Tillerson JL, Caudle WM, Reveron ME, Miller GW. 2002. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp Neurol 178:80-90.
37. Tillerson JL, Caudle WM, Reveron ME, Miller GW. 2003. Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease. Neuroscience 119:899-911.
38. Tillerson JL, Cohen AD, Philhower J, Miller GW, Zigmond MJ, Schallert T. 2001. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J Neurosci 21:4427-4435.
39. Tillerson JL, Miller GW. 2002. Forced limb-use and recovery following brain injury. Neuroscientist 8:574-585.
40. Towbin H, Staehelin T, Gordon J. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Procedures and some applications. Proc Natl Acad Sci USA 76:4350-4354.